Background:  This is a randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to a NOAC (apixaban) in patients with atrial fibrillation.  Trial Registration No: EudraCT: 2019-002365-35  Sponsor:  Bayer  Trial Status: recruiting  Enrolling Centers:  Worldwide: Number of patients needed: 800  Core Study Team Basel:
© Christian Mueller, 2012 - 2020 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: Mai 2020
Home News Team Studies Publications Events Cooperations Contact Kristin Shrestha Beate Hartmann Ph.D. Eleni Michou Prof. Christian Müller Prof. Michael Kühne Ina-Maria Ferel Ph.D. Prof. Danielle Menosi  Gualandro Juliane Gehrke Hadrian Schöpfer